ストックスクリーナーアプリを入手
52.85
1.03%
-0.55
前日終値:
$53.40
開ける：
$52.4
24時間の取引高:
4.26M
Relative Volume:
1.29
時価総額：
$23.43B
収益：
$2.44B
当期純損益:
$1.36B
株価収益率:
27.68
EPS:
1.9093
ネットキャッシュフロー:
$574.14M
1週間 パフォーマンス:
+4.06%
1か月 パフォーマンス:
+8.52%
6か月 パフォーマンス:
+34.96%
1年 パフォーマンス:
+59.57%
1日の値動き範囲:
$52.04
$53.02
1週間の範囲:
$50.48
$53.47
52週間の値動き範囲:
$32.15
$53.47
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
52.85 | 23.67B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Qsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRX - MarketBeat
Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance UK
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead - Seeking Alpha
Royalty Pharma EVP Urist sells $726,137 in shares - Investing.com
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan - Stock Titan
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden - Stock Titan
Understanding the Setup: (RPRX) and Scalable Risk - Stock Traders Daily
Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend - Moomoo
Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares - Stock Titan
[144] Royalty Pharma plc SEC Filing - Stock Titan
Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma - Stock Titan
Royalty Pharma stock hits 52-week high at 52.16 USD By Investing.com - Investing.com Nigeria
RPRX: Expanding royalty financing, robust pipeline, and strong capital position drive future growth - TradingView
Royalty Pharma stock hits 52-week high at 52.16 USD - Investing.com India
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Healthcare Giant with a Promising 16.66% Potential Upside - DirectorsTalk Interviews
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts - Morningstar
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - MSN
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth By Investing.com - Investing.com India
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
Royalty Pharma Plc (RPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Norden Gregory | Director |
May 14 '26 |
Sale |
53.00 |
3,045 |
161,385 |
191,803 |
5.60%
大文字化:
|
ボリューム (24 時間):